Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SMN
|
|||
| Former ID |
DIB010935
|
|||
| Drug Name |
POP-1
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1], [2] | |
| Company |
Propanc Pty Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-glucosidase (GLA) | Target Info | Modulator | [1], [2] |
| Cationic trypsinogen (PRSS1) | Target Info | Modulator | [1], [2] | |
| Chymotrypsin (CTR) | Target Info | Modulator | [1], [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pancreatic secretion | ||||
| Protein digestion and absorption | ||||
| Influenza A | ||||
| Reactome | Activation of Matrix Metalloproteinases | |||
| Cobalamin (Cbl, vitamin B12) transport and metabolism | ||||
| WikiPathways | Activation of Matrix Metalloproteinases | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | |||
| REF 2 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.